Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections; Data Show Favorable Safety And Tolerability With Dosing Up To 800 Mg For 10...
Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections; Data Show Favorable Safety And Tolerability With Dosing Up To 800 Mg For 10...
Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections; Data Show Favorable Safety And Tolerability With Dosing Up To 800 Mg For 10 Days; Plans To Initiate Human Challenge Study In 2025 In Norovirus-infected Subjects
Cocrystal Pharma报告了口服广泛作用抗病毒药物CDI-988在预防和治疗诺如病毒、冠状病毒及其他病毒感染方面的第一阶段结果；数据显示，在每天最高达800毫克的剂量下，安全性和耐受性良好，持续10天；计划在2025年在诺如病毒感染者中启动人类挑战研究。
- Data show favorable safety and tolerability with dosing up to 800 mg for 10 days
- Plans to initiate human challenge study in 2025 in norovirus-infected subjects
- 数据显示，在每天最高达800毫克的剂量下，安全性和耐受性良好，持续10天。
- 计划在2025年在诺如病毒感染者中启动人类挑战研究。
BOTHELL, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces favorable safety and tolerability results at dosing up to 800 mg per day for 10 consecutive days from the multiple-ascending dose (MAD) portion of the ongoing Phase 1 study with its oral protease inhibitor CDI-988, the first pan-viral drug candidate in development as an orally administered treatment of norovirus and coronavirus infections. The Company also announces that an additional cohort with a higher dose of 1,200 mg and a shorter treatment duration of five consecutive days will be conducted to further assess CDI-988's safety, tolerability and pharmacokinetics.
华盛顿州博塞尔，2025年1月8日（全球新闻热线）——Cocrystal Pharma, Inc.（纳斯达克：COCP）（"Cocrystal"或"公司"）宣布在进行中的第一阶段研究中，口服蛋白酶抑制剂CDI-988的递增多次剂量（MAD）部分中，日剂量高达800毫克的安全性和耐受性结果良好，持续10天。该公司还宣布，将进行一个额外的队列，给予更高剂量的1200毫克和更短的治疗持续时间（连续五天），以进一步评估CDI-988的安全性、耐受性和药代动力学。
